Early Laparoscopic Ileal Resection for Localized Ileocecal Crohn's Disease: Hard Sell or a Revolutionary New Norm?
- PMID: 35224013
- PMCID: PMC8820134
- DOI: 10.1159/000515959
Early Laparoscopic Ileal Resection for Localized Ileocecal Crohn's Disease: Hard Sell or a Revolutionary New Norm?
Abstract
Background: Despite reductions in surgical rates that have been observed with earlier use of biological therapy, surgery still constitutes an important tool in the therapeutic armamentarium in Crohn's disease (CD), particularly in patients with stenotic and penetrating phenotypes. In these scenarios, early surgical intervention is recommended, as bowel damage is present and irreversible, leading to lower efficacy with biologics.
Summary: The concept of early surgery in CD supposes the possible advantages of better surgical outcomes in luminal CD after initial resection. Optimal timing of surgical intervention is associated with better postoperative outcomes, whilst delays can lead to more technically difficult and extensive procedures, which may result in an increase in postoperative complication rates and higher rates of stoma formation. Furthermore, data from the LIR!C trial have demonstrated that early surgery in luminal localized inflammatory ileocecal CD is an adequate alternative to medical therapy, with lower societal costs in the long term. In this review, we discuss the position of early resection in ileocecal CD by critically reviewing available data, describing the ideal patients to be considered for early surgery, and weighing the potential advantages and disadvantages of an early surgery paradigm.
Key messages: While early surgery may not be the right choice for every patient, the ultimate decision regarding whether surgical or medical therapy should come first in the treatment paradigm must be individualized for each patient based on the disease characteristics, phenotype, risk factors, and personal preference. This highlights the importance of the multidisciplinary team, which remains a key pillar in deciding the overall management plan for patients with CD.
Keywords: Crohn's disease; Laparoscopy; Surgery.
Copyright © 2021 by S. Karger AG, Basel.
Conflict of interest statement
Christopher Ma has received consulting fees from Robarts Clinical Trials. Remo Panaccione has received consulting and speaker fees from AbbVie, Allergan, Celgene, Eli Lily, Ferring, Gilead, Janssen, Shire, and Takeda; served as a Scientific Advisory Board member for AbbVie, Allergan, Celgene, Eli Lily, Janssen, and Takeda; and received research grants from AbbVie, Janssen, and Takeda. Paulo Kotze has received consulting and speaker fees from AbbVie, Janssen, Pfizer, Takeda, and UCB. Beatriz Maruyama has no conflicts of interest.
Comment in
-
Earlier surgery is associated to reduced postoperative morbidity in ileocaecal Crohn's disease: Results from SURGICROHN - LATAM study.Dig Liver Dis. 2023 May;55(5):589-594. doi: 10.1016/j.dld.2022.09.011. Epub 2022 Oct 28. Dig Liver Dis. 2023. PMID: 37113020
Similar articles
-
Short-Term Results of Operative Treatment of Primary Ileocecal Crohn's Disease: Retrospective, Comparative Analysis between Early (Luminal) and Complicated Disease.J Clin Med. 2023 Apr 1;12(7):2644. doi: 10.3390/jcm12072644. J Clin Med. 2023. PMID: 37048726 Free PMC article.
-
Laparoscopic ileocecal resection in Crohn's disease: a case-matched comparison with open resection.Surg Endosc. 2003 May;17(5):814-8. doi: 10.1007/s00464-002-9103-4. Epub 2003 Jan 18. Surg Endosc. 2003. PMID: 12584603
-
Advantages of laparoscopic resection for ileocecal Crohn's disease.Dis Colon Rectum. 2002 May;45(5):605-10. doi: 10.1007/s10350-004-6253-6. Dis Colon Rectum. 2002. PMID: 12004208
-
A comprehensive review and update on Crohn's disease.Dis Mon. 2018 Feb;64(2):20-57. doi: 10.1016/j.disamonth.2017.07.001. Epub 2017 Aug 18. Dis Mon. 2018. PMID: 28826742 Review.
-
Visceral adiposity and inflammatory bowel disease.Int J Colorectal Dis. 2021 Nov;36(11):2305-2319. doi: 10.1007/s00384-021-03968-w. Epub 2021 Jun 9. Int J Colorectal Dis. 2021. PMID: 34104989 Review.
Cited by
-
Timing of individualized surgical intervention in Crohn's disease.World J Gastrointest Surg. 2022 Dec 27;14(12):1320-1328. doi: 10.4240/wjgs.v14.i12.1320. World J Gastrointest Surg. 2022. PMID: 36632120 Free PMC article. Review.
-
Surgery for Crohn's disease: upfront or last resort?Gastroenterol Rep (Oxf). 2022 Nov 9;10:goac063. doi: 10.1093/gastro/goac063. eCollection 2022. Gastroenterol Rep (Oxf). 2022. PMID: 36381220 Free PMC article. Review.
-
Short-Term Results of Operative Treatment of Primary Ileocecal Crohn's Disease: Retrospective, Comparative Analysis between Early (Luminal) and Complicated Disease.J Clin Med. 2023 Apr 1;12(7):2644. doi: 10.3390/jcm12072644. J Clin Med. 2023. PMID: 37048726 Free PMC article.
-
The patient and clinician perspective on 'early' bowel resection for terminal ileal Crohn's disease (EBRIC): protocol for a multicentre mixed-methods study.Colorectal Dis. 2025 Mar;27(3):e70042. doi: 10.1111/codi.70042. Colorectal Dis. 2025. PMID: 40025798 Free PMC article.
-
Surgical treatment of inflammatory bowel disease: From the gastroenterologist's stand-point.World J Gastrointest Surg. 2024 May 27;16(5):1235-1254. doi: 10.4240/wjgs.v16.i5.1235. World J Gastrointest Surg. 2024. PMID: 38817292 Free PMC article.
References
-
- Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, et al. Crohn's disease. Nat Rev Dis Primers. 2020;6((1)):22. - PubMed
-
- Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease the CHARM trial. Gastroenterology. 2007;132((1)):52–65. - PubMed
-
- Colombel J-F, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, et al. Effect of tight control management on Crohn's disease [CALM] a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;6736((17)):1–11. - PubMed
-
- Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016;375((20)):1946–60. - PubMed
-
- Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, et al. Early combined immunosuppression for the management of Crohn's disease [REACT] a cluster randomised controlled trial. Lancet. 2015;386((10006)):1825–34. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous